Talacotuzumab

Drug Profile

Talacotuzumab

Alternative Names: CSL 362AML; CSL-362; IL-13 MAb - CSL; JNJ 473; JNJ 56022473

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSL
  • Developer CSL; Janssen Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin-3-receptor-alpha-subunit-antagonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes
  • Preclinical Systemic lupus erythematosus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Monotherapy, Second-line therapy or greater) in Australia (IV, Infusion)
  • 17 May 2017 Johnson & Johnson Pharmaceuticals announces intention to submit regulatory filings for talacotuzumab in Acute myeloid leukaemia in between 2017 and 2021
  • 09 May 2017 Phase-III clinical trials in Acute myeloid leukaemia (Combination therapy, In the elderly, Second-line therapy or greater) in Belgium, Spain, USA, Germany, Israel, Russia, Australia, United Kingdom, Taiwan, Poland, South Korea, Turkey, Sweden, France (IV) (NCT02472145)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top